Plain-English translation of NCT05997693 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After coronary artery bypass grafting (CABG) — a surgical procedure to improve blood flow to the heart — doctors typically prescribe aspirin to help prevent blood clots. This trial is testing whether adding ticagrelor, another blood-thinning medication, for just one month after surgery provides extra protection against heart attacks, strokes, and graft failure compared to aspirin alone.
Even after bypass surgery, some patients experience blood clots that can block their new grafts or cause serious complications like heart attacks or strokes. Researchers want to know if using this additional medication early on can reduce these risks without causing excessive bleeding.
You likely qualify if…
You likely don't qualify if…
After you have your bypass surgery, you will be randomly assigned to either take the new medication (ticagrelor plus aspirin) or aspirin alone for one month. You'll then continue with standard care and return for scheduled check-ups over the next five years so researchers can track whether you experience any heart problems, strokes, or other complications. Throughout the study, doctors will monitor you closely and ask about any bleeding or side effects.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States
Austria